Analyst Ratings For NASDAQ:NBRV – Nabriva Therapeutics (NASDAQ:NBRV)
Today, Northland Securities initiated coverage on NASDAQ:NBRV – Nabriva Therapeutics (NASDAQ:NBRV) with a Outperform.
Some recent analyst ratings include
- 5/31/2018-Northland Securities initiated coverage with a Outperform rating.
- 5/8/2018-Needham & Company LLC Reiterated Rating of Buy.
- 3/19/2018-Wedbush Reiterated Rating of Outperform.
- 1/17/2018-Morgan Stanley initiated coverage with a Overweight ➝ Overweight rating.
- 11/16/2017-HC Wainwright Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:NBRV – Nabriva Therapeutics (NASDAQ:NBRV)
NASDAQ:NBRV – Nabriva Therapeutics (NASDAQ:NBRV) has insider ownership of 2.75% and institutional ownership of 68.88%.
- On 5/23/2018 Francesco Maria Lavino, Insider, bought 2,160 with an average share price of $4.60 per share and the total transaction amounting to $9,936.00.
- On 5/23/2018 Gary Sender, CFO, bought 2,000 with an average share price of $4.57 per share and the total transaction amounting to $9,140.00.
- On 5/23/2018 Robert Crotty, General Counsel, bought 10,000 with an average share price of $4.48 per share and the total transaction amounting to $44,800.00.
- On 5/23/2018 Stephen W Webster, Director, bought 8,000 with an average share price of $4.59 per share and the total transaction amounting to $36,720.00.
- On 11/29/2017 Francesco Maria Lavino, Insider, bought 1,569 with an average share price of $6.29 per share and the total transaction amounting to $9,869.01.
- On 9/22/2017 Colin Md Broom, CEO, bought 2,588 with an average share price of $8.35 per share and the total transaction amounting to $21,609.80.
- On 9/22/2017 Gary Sender, CFO, bought 2,000 with an average share price of $8.21 per share and the total transaction amounting to $16,420.00.
Recent Trading Activity for NASDAQ:NBRV – Nabriva Therapeutics (NASDAQ:NBRV)
Shares of NASDAQ:NBRV – Nabriva Therapeutics closed the previous trading session at 4.57 up +0.20 4.58% with 217699 shares trading hands.